Role of oxidative stress in respiratory diseases and its monitoring;Papel del estrés oxidativo en las enfermedades respiratorias y su monitorización

Medicina Clinica

Volumn 127, Issue 10, 2006, Pages 386-396

  Ramírez Prieto, María Teresa ^a,b   García Río, Francisco ^a   Villamor, José ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

Acute respiratory distress; Asthma; Bronchectases; COPD; Cystic fibrosis; Exhaled carbon monoxide; Exhaled gas condensate; Exhaled nitric oxide; Inflammation; Interstitial lung diseases; Oxidative stress; SOAS

Indexed keywords

CARBON MONOXIDE; HYDROGEN PEROXIDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; STEROID; SUPEROXIDE; TOBACCO SMOKE;

AIRWAY OBSTRUCTION; ASTHMA; CELL DAMAGE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATORY CELL; INTERSTITIAL LUNG DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 33750084729     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13092440     Document Type: Review

References (148)

1. Dröge W. Free radical in the physiological control of cell function. Physiol Rev. 2002;82:47-95.
2. Henricks AJP, Nijkamp FP. Reactive oxygen species as mediators in asthma. Pulm Pharmacol Ther. 2001;14:409-21.
3. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest. 1982;47:412-26.
4. Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, Saul RL, et al. Oxygen radicals and human disease. Ann Intern Med. 1987;107:526-45.
5. Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med. 1992;119:598-620.
6. Chow C, Herrera Abreu MT, Suzuki T, Downey GP. Oxidative stress and acute lung injury. Am J Respir Cell Moll Biol. 2003;29:427-31.
7. Deby C, Goutier R. New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutasa. Biochem Pharmacol. 1990;39:399-405.
8. Fridovich I. The biology of oxygen radicals. Science. 1978;201:875-80.
9. Chance B, Sies H, Boveries A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;58:527-605.
10. William MacNee. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol. 2001;429:195-207.
11. Babior BM, Kipnes RS, Curnutte JT. Biological defence mechanisms. The production by leukocytes of superoxide, a potential bacterial agent. J Clin Invest. 1973;52:741-6.
12. Brunori M, Rotilio G. Biochemestry of oxigen radical species. Meth Enzymol. 1984;105:22-35.
13. Fisher AB, Al-Mehdi AB, Wei Z, Song C, Manevich Y. Lung ischemia: endothelial cell signalling by reactive oxygen species. A progress report. Adv Exp Med Biol. 2003;510:343-7.
14. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem. 2003;278:12094-100.
15. Parinandi NL, Kleinberg MA, Usatyuk PV, Cummings RJ, Pennathur A, Cardounel AJ, et al. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinase in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L26-L38.
16. Stewart RM, Weir EK, Montgomery MR, Niewoehner D. Hydrogen peroxide contracts airways smooth muscle: a possible endogenous mechanism. Respir Physiol. 1981;45:333-42.
17. Abe MK, Chao TSO, Solway J, Rosner MR, Hershenson MB. Hydrogen peroxide stimulates mitogen activated protein kinase in bovine tracheal myocytes: implications for human disease. Am J Respir Cell Mol Biol. 1994;11:577-85.
18. Ikuta O, Sugiyama S, Takagi K, Satake T, Ozawa T. Implication of oxygen radicals on airway hyperresponsiveness after ovalbumin challenge in guinea pigs. Am Rev Respir Dis. 1992;145:561-5.
19. Ambrosio G, Trito I, Golino P. Reactive oxygen metabolites and arterial trombosis. Cardiovasc Res. 1997;34:445-52.
20. Lai YH, Barnes PJ, Rogers DF. Involvement of hydroxyl radicals in neurogenica airway plasma exudation and bronchoconstriction in guinea-pigs in vivo. Brit J Pharmacol. 1996;117:449-52.
21. Ohrui T, Sekizawa K, Yamauchi K, Ohkawara Y, Nakazawa H, Aikawa T, et al. Chemical oxidant potentates electrically and acetylcholine-induced contraction in rat trachea: possible involvement of cholinesterase inhibition. J Pharmacol Exp Ther. 1991;259:371-6.
22. Krishna MT, Springall D, Meng QH, Withers N, Macleod D, Biscione G, et al. Effect of ozone on epithelium and sensory nerves in the bronchial mucosa of healthy humans. Am J Respir Crit Care Med. 1997;156:943-50.
23. Barnes PJ, Karin M. Nuclear factor-κβ-A pivotel transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-71.
24. Henricks PAJ, Nijkamp FP. Pharmacological modulation of cell adhesion molecules. Eur J Pharmacol. 1998;344:1-13.
25. Choi AMK, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel sress-inducable protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol. 1996;15:9-19.
26. Wong HR, Wispé JR. The stress response and the lung. Am J Physiol. 1997;273 Suppl 3:1-9.
27. Paredi P, Leckie MJ, Horvath I, Allegra L, Kharitonov SA, Barnes PJ. Changes in exhaled carbon monoxide and nitric oxide levels following allergen challenge in patients with asthma. Eur Respir J. 1999;13:48-52.
28. Salmon M, Koto H, Lynch OT, Haddad EB, Lamb NJ, Quilan GJ, et al. Proliferation of airway epithelium after ozone exposure. Effect of apocynin and dexamethasone. Am J Respir Crit Care Med. 1998;157:970-7.
29. Hulsmann AR, Raatgeep HR, Den Hollander JC, Stinjnen T, Saxena PR, Kerrebijin KF, et al. Oxidative epithelial damage produces hyperresponsiveness of human peripheral airways. Am J Respir Crit Care Med. 1994;149:519-25.
30. Bowler RP, Crapo JD. Oxidative stress in airways. Is there a role for extracellular superoxide dismutase? Am J Respir Crit Care Med. 2002;166:538-543.
31. Smith U, Shamasuddin M, Sporn PH, Denenberg M, Anderson J. Reduced superoxide dismutase in lung cells of patients with asthma. Free Radic Biol Med. 1997;22:1301-7.
32. Assad AH, Ballard ET, Sebastian KD, Loven DP, Boivin GP, Lier MB. Effect of superoxide dismutase on a rabbit model of chronic allergic asthma. Ann Allergy Asthma Immunol. 1998;80:215-24.
33. Dworski R. Oxidant stress in asthma. Thorax. 2000;55 Suppl 1:51-53.
34. Calhoun WJ, Reed HE, Moest DR, Stevens CA. Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. Am Rev Respir Dis. 1992;145:317-25.
35. Jarjour NN, Busse WW, Calhoun WJ. Enhanced production of oxygen radicals in nocturnal asthma. Am Rev Respir Dis. 1992;146:905-11.
36. Dohlman AW, Black HR, Royal JA. Expired breath hydrogen peroxide is a marker of acute airway inflammation in paediatric patients. Am Rev Respir Dis. 1993;148:955-60.
37. Antezak A, Nowak D, Shariati B, Krol M, Piasecka G, Kurmanowska Z. Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients. Eur Respir J. 1997;10:1235-41.
38. 2-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am J Respir Crit Care Med. 1999;160:1947-51.
39. Bowler RP, Crapo JD. Oxidative stress in allergic respiratory diseases. J Allergy Clin Immunol. 2002;110:349-56.
40. Keating VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma and normal subject. Am J Respir Crit Care Med. 1997;155:449-53.
41. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agustí A, et al. Oxidative stress and airway inflammation in severe exacerbation of COPC. Thorax. 2005;60:293-300.
42. Bhowmik A, Seemungal TA, Spasford RJ. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbation. Thorax. 2000;55:114-20.
43. Drost EM, Ritchie HE, Skwarska E. NF-κβ in airway leucocytes in COPD patients. Eur Respir J. 2001;16:260S.
44. MacNee W, Wiggs B, Belzberg AS, Selby C. The effect of cigarette smoking on neutrophilic kinetics in human lungs. N Engl J Med. 1989;321:924-8.
45. Lee W, Downey GP. Neutrophilic activation and acute lung injury. Curr Opin Crit Care 2001;7:1-7.
46. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2:319-23.
47. Rocksen D, Ekstrand-Hammarstrom B, Johansson L, Bucht A. Vitamin E reduces transendothelial migration of neutrophils and prevents lung injury in endotoxin-induced airway inflammation. Am J Respir Cell Mol Biol. 2003;28:199-207.
48. Hoffmann M, Bybee K, Accurso V, Somers VK. Sleep apnoea syndrome and hypertension. Minerva Med. 2004;95:281-90.
49. Young T, Palta M, Dempsey J, Slatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230-5.
50. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnoea: implications for cardiac and vascular disease. JAMA. 2003;8:1906-14.
51. Dhillon S, Chung SA, Fargher T, Huterer N, Shapiro CM. Sleep apnoea, hypertension, and the effects of continuous positive airway pressure. Am J Hypertens. 2005;18:594-600.
52. García-Río F, Racionero MA, Pino JM, Martínez I, Ortuño F, Villasante C, et al. Sleep apnea and hypertension. The role of chemoreceptores and the sympathetic system. Chest. 2000;117:1417-25.
53. García-Río F, Pino JM, Alonso A, Arias MA, Martínez I, Álvaro D, et al. Frequency and determinants of white coat hypertension in patients with OSAHS. Chest. 2004;125:817-22.
54. Sin DD, Fitzgerald F, Parker JD, Newton GE, Logan AG, Floras JS. Relationship of systolic BP to obstructive sleep apnoea in patients with heart failure. Chest. 2003;123:1536-43.
55. Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, Wexler L. Sleep apnoea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation. 1998;97:2154-9.
56. Arias MA, García-Río F, Alonso-Fernández A, Mediano O, Martínez I, Villamor J. Obstructive sleep apnoea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation. 2005;19:375-83.
57. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ. Sleep-disordered breathing and cardiovascular disease: cross-sectional result of the Sleep Heart Study. Am J Respir Crit Care Med. 2001;163:19-25.
58. Good DC, Henkle JQ, Gelber D, Welsh J, Vershulst S. Sleep-disordered breathing and poor functional out-come after stroke. Stroke. 1996;27:252-9.
59. Wessendorf TE, Dahm C, Teschler H. Prevalence and clinical importance of sleep apnoea in the first night after cerebral infarction. Neurology. 2003;60:1053.
60. Mooe T, Gullsby S, Rabben T, Eriksson P. Sleep-disordered breathing: a novel predictor of atrial fibrillation after coronary artery bypass surgery. Coron Artery Dis. 1996;7:475-8.
61. Kanagala R, Murali NS, Friedman PA, Ammash NM, Gersh BJ, Ballman KV. Obstructive sleep apnea and recurrence of atrial fibrillation. Circulation. 2003;107:2589-94.
62. Alonso-Fernández A, García-Río F, Racionero MA, Pino JM, Ortuño F, Martínez I, et al. Cardiac rhythm disturbances and ST-segment depression episodes in patients with obstructive sleep apnea-syndrome and its mechanisms. Chest. 2005;127:15-22.
63. Barceló A, Barbé F. Estrés oxidativo y síndrome de apnea-hipopnea del sueno. Arch Bronchoneumol. 2005;41:293-9.
64. Dean RT, Wilcox I. Possible atherogenic effects of hypoxia during obstructive sleep apnea. Sleep. 1993;16:S15-S21.
65. Jaimes EA, Galeeren JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int. 1998;54:775-84.
66. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912-6.
67. Somers MJ, Harrison DG. Reactive oxygen species and the control of vasomotor tone. Curr Hypertens Rep. 1999;1:102-8.
68. Alonso-Fernández A, García-Río F, Arias MA, Mediano O, Pino JM, Martínez I, et al. Obstructive sleep apnoea syndrome reversibly depresses cardiac response to exercise. Eur Heart J. 2006;27:207-15.
69. Van der Vliet A, Eiserich JP, Marelich GP, Halliwell B, Cross CE. Oxidative stress in cystic fibrosis: does it occur and does it matter? Adv Pharmacol. 1997;272:7617-25.
70. Greene K, Takasugi J, Burke W, Godwin D, Aitken M. CXR changes are seen in acute exacerbations in adult CF patients. AJR. 1994;163:557-62.
71. Cystic Fibrosis Foundation. Patient Registry 1995 Annual Data Report. Bethesda: Maryland; 1996.
72. Bakare N, Rickerts V, Bargon J, Just-Nubling G. Prevalence of Aspergilus fumigatus and other species in sputum of adult patient with cystic fibrosis. Mycoses. 2003;46:19-23.
73. Berger M. Inflammation in the lung in cystic fibrosis: a vicious cycle that does more harm than good? Clin Rev Allergy. 1991;9:119-42.
74. Carlstedt-Duke J, Bronnegard M, Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci U S A. 1986;83:9202-6.
75. 4: metabolism and signal transduction. Arch Biochem Biophys. 2001;385:231-41.
76. Spencer DA, Sampson AP, Green CP, Costello JF, Piper PJ, Price JF. Sputum cysteinyl-leukotriene levels correlate with severity of pulmonary disease in children with cystic fibrosis. Pediatr Pumonol. 1992;12:90-4.
77. Zakrzewski JT, Barnes NC, Piper PJ, Costello JF. Detection of sputum eicosanoides in cystic fibrosis and in normal saliva bioassay and radioimmunoassay. Br J Clin Pharmacol. 1987;23:19-27.
78. 4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis. 1993;148:896-901.
79. Henle E, Linn S. Formation, prevention and repair of DNA damage by iron/hydrogen peroxide. J Biol Chem. 1997;272:19095-8.
80. Kinnula V, Crapo JD, Raivio KO. Generation and degradation of reactive oxygen metabolites in the lung. Lab Invest. 1995;73:3-19.
81. - induced alveolar epithelial cell DNA damage. Am J Respir Cell Mol Biol. 2004;31:107-13.
82. Cantin AM, North SL, Fells GA, Hubbard R, Crystal RG. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987;79:1665-73.
83. Saleh D, Barnes PJ, Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:1763-9.
84. Montuschi P, Ciabattoni G, Paredi P. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med. 1998;158:1524-7.
85. Rahman I, Skwarska E, Henry M. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med. 1999;27:60-8.
86. Furchgott R, Zawadzki JV. The original role of endothelial cells in relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.
87. Palmer RJM, Ferrigo AG, Moncada S. Vascular endothelial cells synthesis nitric oxide from L-arginine. Nature. 1987;325:664-6.
88. Gillspie JS. The rat anococcygeus muscle and its response to nerve stimulation and to some drugs. Br J Pharmacol. 1972;45:404-16.
89. Garthawaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggest a role as intercellular messenger in the brain. Nature. 1988;336:385-8.
90. Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun. 1988;157:87-94.
91. Dinerman JL, Steiner JP, Dawson TM, Dawson V, Snyder SH. Cyclic nucleotide dependent phosphorylation of neuronal nitric oxide synthesis inhibits catalytic activity. Neuropharmacology. 1994;33:1245-51.
92. Watkins DN, Peroni DJ, Baskain KA, Garlepp MJ, Thomson PJ. Expression and activity of nitric oxide synthesis in human airway epithelium. Am J Respir Cell Mol Biol. 1997;16:629-39.
93. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-6.
94. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. Eur Respir J. 1997;10:1683-93.
95. Slutsky AS, Drazen JM. Recommendations for standardized procedures for online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. Am J Respir Crit Care Med. 1999;155:2104-17.
96. Khartitonov SA, Barnes PJ. Clinical aspects of exhaled nitric oxide. Eur Respir J. 2000;16:781-92.
97. Kharitonov SA. Exhaled nitric oxide and carbon monoxide in asthma. Eur Respir J. 1999;9:212-8.
98. Gustafsson LE. Exhaled nitric oxide as a marker in asthma. Eur Respir J. 1998;26 Suppl 1:49-52.
99. Kharitonov SA, Chung FK, Evans DJ, O'Connor BJ, Barnes PJ. The elevated level of exhaled nitric oxide in asthmatic patients in mainly derived from the lower respiratory tract. Am J Respir Crit Care Med. 1996;153:1773-80.
100. Massaro AF, Mehta S, Lilly CM, Kobzik L, Reilly JJ, Drazen JM. Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects. Am J Respir Crit Care Med. 1996;153:1510-4.
101. Kharitonov SA, Wells AU, O'Connor BJ, Cole PJ, Hansell DM, Logan-Sinclair RB, et al. Elevated levels of exhaled nitric oxide in bronchiectasias. Am J Respir Crit Care Med. 1995;151:1889-93.
102. Maziak W, Loukides S, Culpitt SV, Sullivan P, Karithonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:998-1002.
103. Moodley YP, Chetty R, Lallo UG. Nitric oxide levels in exhaled air and inducible nitric oxide synthesis immunolocalization in pulmonary sarcoidosis. Eur Respir J. 1999;14:822-7.
104. Ten Hacken NHT, Van der Vaart H, Van der Mark TW, Köeter GH, Postma DS. Exhaled nitric oxide is higher both at day and night in subjects with nocturnal asthma. Am J Respir Crit Care Med. 1996;154:247-50.
105. Grasemann H, Ioannidis I, De Groot H, Ratjen F. Metabolites of nitric oxide in the lower respiratory tract of children. Eur J Pediatr. 1997;156 :575-8.
106. Kharitonov SA, Barnes PJ, O'Connor BJ. Reduction in exhaled nitric oxide after single dose of nebulized budesonide in patients with asthma. Am J Respir Crit Care Med. 1996;153:A799.
107. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996;153:454-7.
108. Kharitonov SA, Yates DH, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994;343:133-5.
109. Artlich A, Busch T, Lewandowski K, Jonas S, Gortner L, Falke KJ. Childhood asthma: exhaled nitric oxide in relation to clinical symptoms. Eur Respir J. 1999;13:1396-401.
110. Kobayashi H, Takhashi Y, Mitsufuji H, Hataishi R, Cui T, Tanaka N, et al. Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast. Jpn J Physiol. 1999;49:541-4.
111. García-Río F, Ramírez M, Mediano O, Lores V, RoJo B, Taylor DR, etal. Exhaled nitric oxide and airway caliber during exercise-induced bronchoconstriction. Int J Sport Med. En prensa 2005.
112. Paredi P, Karitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:369-73.
113. Maegher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoides on the rate of apoptosis in neutrophilic an eosinophilic granulocytes. J Immunol. 1996;156:4422-8.
114. Haldane J. The action of carbon monoxide on man. J Physiol. 1895;18:30.
115. Nicloux M. Suf l'oxide de carbone contenn normalment dans le sang. CR Acad Sci (Paris). 1898;126:1526-8.
116. Nicloux M, Nebenzahl H. Etude de l'oxydation des sucres en solution alcaline par l'oxygene gazeus. CR Soc Biol (Paris). 1901;101:189-202.
117. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenize. Proc Natl Acad Sci U S A. 1968;61:748-55.
118. Berk PD, Rodkey FL, Blaschke TF, Collison HA, Waggoner JG. Comparison of plama bilirubin turnover and carbon monoxide production in man. J Lab Clin Med. 1974;83:29-37.
119. Nikberg II, Murashko VA, Leonenko IN. Carbon monoxide concentration in the air exhaled by the healthy and the ill. Vrach Celo. 1972;12:112-4.
120. Kharitonov SA, Paredi P, Barnes PJ. Reproducibility of exhaled carbon monoxide measurements and its circadian variation in normal subjects. Am J Respir Crit Care Med. 1998;157 Suppl 4:613.
121. Paredi P, Shah PL, Montuschi P, Sullivan P, Hodson ME, Kharitonov SA, et al. Increased carbon monoxide in exhaled air of cystic fibrosis patients. Thorax. 1999;54:917-20.
122. Montuschi P, Kharitonov SA, Ciabattoni G, Corradi M, Van Resen L, Geddes DM, et al. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stess in cystic fibrosis. Thorax. 2000;55:205-9.
123. Paredi P, Kharitonov SA, Leak D, Shah PL, Cramer D, Hodson ME, et al. Exhaled ethane is elevated in cystic fibrosis and correlates with CO levels and airway obstruction. Am J Respir Crit Care Med. 2000;161:1247-51.
124. Antuni JD, Kharitonov SA, Hughes D, Hodson ME, Barnes PJ. Increases in exhaled carbon monoxide during exacerbations of cystic fibrosis. Thorax. 2000;55:138-42.
125. Muller T, Gebel S. The cellular stress response induced by aqueous extracts of cigarette smoke is critically dependent on the intracellular glutathione concentration. Carcinogenesis. 1998;19:797-801.
126. Delen FM, Sippel JM, Osborone ML, Law S, Thukkani N, Holden WE. Increased exhaled nitric oxide in chronic bronchitis. Comparison with asthma and COPD. Chest. 2000;117:695-701.
127. Culpitt SV, Paredi P, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide is increased in COPD patients regardless of their smoking habit. Am J Respir Crit Care Med. 1998;157 Suppl 3:787.
128. Biernacki W, Kharitonov SA, Barnes PJ. Carbon monoxide in exhaled air in patients with lower respiratory tract infection. Eur Respir J. 1998;12:3455.
129. Antuni JD, Du Bois AB, Ward S, Crames DS, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide may be a marker of deterioration of lung function in cryptogenic fibrosing alveolitis and scleroderma. Am J Respir Crit Care Med. 1999;159 Suppl 1:51.
130. Paredi P, Kharitonov SA, Lokides S, Pantelidis P, Du Bois RM, Barnes PJ. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest. 1999;115:1352-6.
131. Kharitonov SA. Exhaled nitric oxide and carbon monoxide in respiratory diseases other than asthma. Eur Respir J. 1999;29:223-6.
132. Zayasu K, Sekizawa K, Okinaga S, Yamaya M, Ohrui T, Sasaki H. Increased carbon monoxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1997;156:1140-3.
133. Hovarth I, Donnelly LE, Kiss A, Paredi P, Kharitonov SA, Barnes PJ. Elevated levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stess. Thorax. 1998;53:668-72.
134. Yamaya M, Sekizawa K, Ishizuka M, Monma M, Sasaki H. Exhaled carbon monoxide levels during treatment of acute asthma. Eur Respir J. 1999;13:757-60.
135. Stirling RG, Lim S, Kharitonov SA, Chung EK, Barnes PJ. Exhaled breath carbon monoxide is minimally elevated in severe but not mild atopic asthma. Am J Respir Crit Care Med. 2000;161 Suppl 5:922.
136. Biernacki W, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide measurements can be used in general practice to predict the response to oral steroid treatment in patients with asthma. Am J Respir Crit Care Med. 1999;159 Suppl 4:631.
137. Sheffer AI. International consensus report on the diagnosis and management of asthma. Clin Exp Allergy. 1992;22 Suppl 1:1-72.
138. Ramírez M, García-Rio F, Aleydis Viñas A, Prados C, Pino JM, Villamor León J. Relationship between exhaled carbon monoxide and airway hyperresponsiveness in asthmatic patients. J Asthma. 2004;41:109-16.
139. Aulik IV. Gas chromatographic analysis of exhaled air and acetylene mixture. Bull Exp Biol Med. 1966;62:115-7.
140. Paredi P, Kharitonov SA, Barnes PJ. Elevation of exhaled ethane concentration in asthma. Am J Respir Crit Care Med. 2000;162:1450-4.
141. Paredi P, Kharitonov SA, Barnes PJ. Analysis of expired air for oxidation products. Am J Respir Crit Care Med. 2002;166:S31-S7.
142. Paredi P, Kharitonov SA, Barnes PJ. Exhaled ethane is elevated in cystic fibrosis and correlates with carbon monoxide synthesis levels and airway obstruction. Am J Respir Crit Care Med. 1999;161:1247-51.
143. Hovarth I, Hunt J, Barnes PJ. Exhaled breath condensate methodological recommendation and unresolved questions. ATS/ERS Task Force. Eur Respir J. 2005;26:523-48.
144. Hovarth I, Donnelly LE, Kiss A, Kharitonov SA, Lim S, Chung FK. Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Am J Respir Crit Care Med. 1998;158:1042-6.
145. Kharitonov SA. Exhaled markers on inflammatory lung diseases: ready for routine monitoring? Swiss Med Wkly. 2004;134:175-92.
146. Corradi M, Montuschi P, Donnelly LE, Pesci A, Kharitonov SA, Barnes PJ. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. Am J Respir Crit Care Med. 2001;163:854-8.
147. Goncharova VA. Borinseko LV, Dotsenko EK, Pkhaznikova MA. Kallikreinkinin indices and biological composition of exhaled condensate in acute bronchitis patients with varying disease course. Klin Med. 1996;74:46-8.
148. Hunt JF, Fang K, Malik R, Snyder A, Malhotra N, Platts-Mills TAE. Endogenous airway acidification. Implications for asthma ptahophysiology. Am J Respir Crit Care Med. 2000;161:694-9.